FDA OK's 1st generic copycats of Otsuka's Abilify
This article was originally published in Scrip
Executive Summary
Otsuka was unsuccessful in preventing the FDA from approving generic versions of the company's schizophrenia and bipolar disorder drug Abilify (aripiprazole).